I have spent the last 11 years sitting in conference planning meetings, color-coding Excel spreadsheets until my eyes blurred, and listening to vendors promise that their latest software will "revolutionize the paradigm." If there is one thing I’ve learned in my time as an oncology program coordinator, it is that a glossy brochure does not equal clinical utility. As we gear up for ASTRO, the air is thick with the promise of AI-driven workflows. But before you get swept up in the demo reels, let’s talk about what actually matters for your team.
I know the drill. You’re coming to the conference to see what’s next in radiation oncology technology, but you’re tired of the buzzwords. You don't need a lecture on "synergy" or "seamless integration." You need to know how these ASTRO AI applications will hold up when you’re three hours behind schedule and the contouring on a complex head and neck case is stalling your planning workflow. If a vendor cannot show you the clinical data behind their AI treatment planning, keep walking.
Beyond the Buzz: Vetting AI in the Clinical Wild
Before you step onto the exhibit floor, do me a favor: open that spreadsheet of yours. If you don’t have one, start one today. You need to map out your sessions, not by the flashy titles, but by the tangible outcomes promised. My biggest pet peeve? Vague agenda descriptions that don't specify the target audience. Are you looking for tools for medical physicists, dosimetrists, or radiation oncologists? If a session doesn’t explicitly state the attendee level—or if it overclaims that a single abstract is going to change the standard of care—cross it off your list.
True AI treatment planning is about efficiency and reduction of inter-observer variability, not magic. At this year's ASTRO, I’m looking for demonstrations that bridge the gap between bench and bedside.
The Four Pillars of Your ASTRO Strategy
To navigate the noise, I recommend categorizing your deep dives into these four critical themes:
- Targeted Therapy and Immunotherapy: How does the AI model account for changing tumor volume in real-time as a patient responds to systemic therapy? Precision Oncology and Biomarkers: Are the planning tools integrating genomic data? Radiomics is great, but it needs to speak the same language as the pathology reports from ASCO or AACR meetings. Clinical Trials and Translational Research: Look for data that shows these models being used in prospective trials, not just retrospective "proof of concept" datasets. Computational Oncology: Focus on the infrastructure—how these tools sit within the NCCN clinical guidelines framework.
The Comparison Table: Vetting Your Vendors
When Find out more you sit down with a vendor, don't just watch the demo. Ask them to fill in the gaps for you. Use this table as a baseline checklist during your conversations:
Criteria What to Ask What to Watch For Dataset Provenance "Was this trained on diverse patient populations?" Avoid "black box" models trained only on a single institution's data. Integration "Does this export directly to our existing OIS?" Look for "seamless" claims that actually require manual re-contouring. Clinical Validation "Where is the peer-reviewed outcome data?" Beware of "AI-driven" labels on features that lack prospective clinical outcomes. Time-to-Task "How many minutes of human oversight are required?" If it takes more time to correct the AI than to do it manually, it’s not a tool; it’s a burden.Connecting the Dots: From ASCO to NCCN
We often treat oncology sub-disciplines like silos, but the best practice happens at the intersections. If you’re at a session discussing AI in contouring, ask the speaker how this interacts with the systemic therapy protocols mentioned in the latest ASCO or AACR updates. If your radiation plan isn't aware of the patient's immunotherapy status or biomarker profile—as guided by NCCN—you’re essentially planning in a vacuum.
Remember, a great clinical paper is not a product roadmap. Just because an abstract showed a 15% reduction in planning time in a controlled environment doesn’t mean your junior dosimetrist will have the same experience on a Monday morning in a high-volume clinic.
The "Monday Morning" Reality Check
This is where I stop being the "editor" and start being the "coordinator." My favorite part of any medical conference isn't the plenary session; it’s the conversation in the hallway right after. If you attend a session on advanced radiation oncology technology, I want you to ask yourself: "What will I do differently on Monday morning?"
If you come back from ASTRO with a suitcase full of pens and a head full of high-level theory, you’ve wasted your hospital’s travel budget. You should come back with a list of three specific workflow adjustments, one clear path to integrating a new software module, or at least a better understanding of why your current process is (or https://smoothdecorator.com/cracking-the-code-immunotherapy-vs-targeted-therapy-for-your-asco-session-prep/ isn't) hitting the benchmarks set by the NCCN.
Final Thoughts: Don't Get Hype-Blind
The tech is exciting. Truly, it is. But as someone who has spent 11 years watching vendors come and go, I urge you to remain skeptical. Don't let the shiny UI distract you from the fact that patient outcomes remain the only metric that actually counts. If the technology can't prove that it helps you make better clinical decisions—or helps you get home on time without sacrificing accuracy—then it’s just another digital distraction.
Make your plan, stick to your schedule, and for heaven's sake, keep that spreadsheet updated. If you find a tool that actually works, I want to hear about it.
Share this guide with your colleagues:
Share on Facebook | Share on X (Twitter)